HSP27 functional switch drives castration-resistant prostate cancer via mTOR pathway activation, highlighting promising combination therapies.

J Exp Clin Cancer Res · 2026 · PMC13085302 · PMID 41877198

Europe PMC DOI

hedged sentence

0.0580

closest p · 1.2× alpha

0.0580

boldest claim

The sentences

showed a trendp = 0.058so close (0.05 < p ≤ 0.1)

Moreover, patients with concurrent high HSP27 and low PTEN expression also showed a trend toward worse outcomes (log-rank test p = 0.058).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.